BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q1 2022
Top Holdings118 positions
SEAGEN INC | 46.9M | $6.8B | 38.8% | — | — | 7 qtrssince 2020-Q3 | Increased 62 |
INCYTE CORP | 36.2M | $2.9B | 16.5% | $85.00 | -6.56% | 13 qtrssince 2019-Q1 | Increased 67 |
BEONE MEDICINES LTD | 11.7M | $2.2B | 12.6% | $149.70 | +25.99% | 13 qtrssince 2019-Q1 | Unchanged 0 |
ACADIA PHARMACEUTICALS INC | 41.9M | $1B | 5.8% | $27.58 | -12.17% | 13 qtrssince 2019-Q1 | Unchanged 0 |
BIOMARIN PHARMACEUTICAL INC | 7.6M | $587.5M | 3.4% | $88.78 | -12.27% | 13 qtrssince 2019-Q1 | Unchanged 0 |
<![CDATA[ASCENDIS PHARMA A/S]]> | 4.5M | $533M | 3.1% | $127.51 | -9.01% | 13 qtrssince 2019-Q1 | Unchanged 0 |
ARGENX SE | 1.1M | $353M | 2.0% | $138.29 | +128.01% | 13 qtrssince 2019-Q1 | Unchanged 0 |
BIOCRYST PHARMACEUTICALS INC | 12.7M | $206.7M | 1.2% | $7.50 | +119.33% | 13 qtrssince 2019-Q1 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC | 1.5M | $147.1M | 0.8% | $112.39 | -12.69% | 13 qtrssince 2019-Q1 | Unchanged 0 |
KODIAK SCIENCES INC | 15.9M | $123M | 0.7% | $36.28 | -78.72% | 13 qtrssince 2019-Q1 | Increased 46 |
MIRATI THERAPEUTICS INC | 1.4M | $115.9M | 0.7% | — | — | 13 qtrssince 2019-Q1 | Unchanged 0 |
GLOBAL BLOOD THERAPEUTICS IN | 3.3M | $114.8M | 0.7% | — | — | 9 qtrssince 2020-Q1 | Unchanged 0 |
ABCELLERA BIOLOGICS INC | 10.5M | $101.9M | 0.6% | $41.10 | -76.28% | 6 qtrssince 2020-Q4 | Unchanged 0 |
KYMERA THERAPEUTICS INC | 2.4M | $100.9M | 0.6% | $37.03 | +14.30% | 7 qtrssince 2020-Q3 | Unchanged 0 |
HORIZON THERAPEUTICS PUB L | 898,842 | $94.6M | 0.5% | — | — | 9 qtrssince 2020-Q1 | Increased 58 |
TRAVERE THERAPEUTICS INC | 3.3M | $85M | 0.5% | $25.43 | -1.25% | 5 qtrssince 2021-Q1 | Increased 43 |
IGM BIOSCIENCES INC | 3.2M | $84.4M | 0.5% | — | — | 11 qtrssince 2019-Q3 | Unchanged 0 |
Invitae Corp | 9.9M | $78.7M | 0.5% | — | — | 13 qtrssince 2019-Q1 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 2.5M | $75.4M | 0.4% | $42.57 | -29.76% | 5 qtrssince 2021-Q1 | Unchanged 0 |
CERUS CORP | 13.7M | $75.3M | 0.4% | $5.89 | -6.77% | 13 qtrssince 2019-Q1 | Unchanged 0 |
BAKER BROS. ADVISORS LP manages $17.4B across 118 positions as of Q1 2022. Top holdings: SGEN (38.8%), INCY (16.5%), ONC (12.6%). Fund DNA: Concentrated Value. HoldingsIntel Score: 3/5.0.
Added 2 new positions, exited 5, increased 15, trimmed 4. Top move: INCY (INCREASED, conviction 67). Portfolio: $17.4B across 118 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Famous Investors' Portfolios
What the most-followed managers hold, and what they bought and sold each quarter.
- Warren Buffett (Chairman Emeritus)Berkshire Hathaway
- Leopold AschenbrennerSituational Awareness
- Michael BurryScion Asset Management
- Cathie WoodARK Invest
- Bill AckmanPershing Square
- Stanley DruckenmillerDuquesne Family Office
- David TepperAppaloosa
- Ray Dalio (Founder)Bridgewater Associates
- Li LuHimalaya Capital
- Carl IcahnCarl C. Icahn
- Brad GerstnerAltimeter Capital
- Seth KlarmanThe Baupost Group
- Howard Marks (Co‑founder)Oaktree Capital Management
- Ken GriffinCitadel
- Paul Tudor JonesTudor Investment Corp
- George Soros (Founder)Soros Fund Management
- Steve CohenPoint72
- Terry SmithFundsmith
- Ken Fisher (Founder)Fisher Investments
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR